Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 10/20 | 0.68 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492747 | 0.81 | ADAMTS5 (0.50) | AVPR1BHTR7MMP13ADAM17ADAMTS5 | |
| SCHEMBL2885086 | 0.80 | AVPR1B (0.51) | AVPR1BADAMTS5 | |
| SCHEMBL2492716 | 0.80 | AVPR1B (0.49) | AVPR1BMMP13ADAM17ADAMTS5MMP2 | |
| SCHEMBL4082406 | 0.78 | AVPR1B (1.00) | AVPR1B | |
| SCHEMBL2499319 | 0.71 | ADAM17 (0.50) | AVPR1BHTR7MMP13ADAM17ADAMTS5 | |
| SCHEMBL4087669 | 0.71 | AVPR1B (0.84) | AVPR1B | |
| SCHEMBL4087487 | 0.71 | AVPR1B (0.78) | AVPR1B | |
| SCHEMBL4077577 | 0.71 | AVPR1B (0.84) | AVPR1B | |
| SCHEMBL2496385 | 0.70 | ADAM17 (0.49) | MMP13ADAM17ADAMTS5MMP2 | |
| SCHEMBL4590696 | 0.69 | BRD4 (0.47) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431567-B2 | Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2066657-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008025735-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885CYP11B2 232/4885HTR7 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.